GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (BUE:BIIB) » Definitions » Shiller PE Ratio

Biogen (BUE:BIIB) Shiller PE Ratio

: 10.19 (As of Today)
View and export this data going back to 2019. Start your Free Trial

As of today (2024-04-19), Biogen's current share price is ARS15650.00. Biogen's E10 for the quarter that ended in Dec. 2023 was ARS1,535.74. Biogen's Shiller PE Ratio for today is 10.19.

The historical rank and industry rank for Biogen's Shiller PE Ratio or its related term are showing as below:

BUE:BIIB' s Shiller PE Ratio Range Over the Past 10 Years
Min: 9.29   Med: 30.16   Max: 110.75
Current: 9.29

During the past years, Biogen's highest Shiller PE Ratio was 110.75. The lowest was 9.29. And the median was 30.16.

BUE:BIIB's Shiller PE Ratio is ranked better than
90.49% of 515 companies
in the Drug Manufacturers industry
Industry Median: 24.57 vs BUE:BIIB: 9.29

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Biogen's adjusted earnings per share data for the three months ended in Dec. 2023 was ARS617.310. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is ARS1,535.74 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Biogen Shiller PE Ratio Historical Data

The historical data trend for Biogen's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.24 15.16 13.53 13.69 12.51

Biogen Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.69 13.49 13.58 12.33 12.51

Competitive Comparison

For the Drug Manufacturers - General subindustry, Biogen's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biogen Shiller PE Ratio Distribution

For the Drug Manufacturers industry and Healthcare sector, Biogen's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Biogen's Shiller PE Ratio falls into.



Biogen Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Biogen's Shiller PE Ratio for today is calculated as

Shiller PE Ratio=Share Price/ E10
=15650.00/1535.74
=10.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biogen's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Biogen's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=617.31/129.4194*129.4194
=617.310

Current CPI (Dec. 2023) = 129.4194.

Biogen Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 16.017 99.695 20.793
201406 24.456 100.560 31.475
201409 30.477 100.428 39.275
201412 31.981 99.070 41.778
201503 30.781 99.621 39.988
201506 35.710 100.684 45.902
201509 39.020 100.392 50.303
201512 48.795 99.792 63.282
201603 64.696 100.470 83.337
201606 66.963 101.688 85.224
201609 70.258 101.861 89.266
201612 47.399 101.863 60.222
201703 53.343 102.862 67.115
201706 67.106 103.349 84.034
201709 101.461 104.136 126.095
201712 -26.924 104.011 -33.501
201803 111.625 105.290 137.207
201806 104.249 106.317 126.902
201809 263.113 106.507 319.716
201812 178.345 105.998 217.752
201903 279.493 107.251 337.265
201906 350.730 108.070 420.019
201909 469.219 108.329 560.568
201912 482.971 108.420 576.515
202003 501.520 108.902 596.010
202006 656.531 108.767 781.189
202009 331.110 109.815 390.221
202012 188.802 109.897 222.342
202103 242.315 111.754 280.618
202106 283.243 114.631 319.783
202109 217.072 115.734 242.740
202112 252.475 117.630 277.780
202203 221.186 121.301 235.989
202206 871.189 125.017 901.869
202209 1,089.368 125.227 1,125.843
202212 635.393 125.222 656.692
202303 527.459 127.348 536.039
202306 976.800 128.729 982.041
202309 -164.477 129.860 -163.920
202312 617.310 129.419 617.310

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Biogen  (BUE:BIIB) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Biogen Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Biogen's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Biogen (BUE:BIIB) Business Description

Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.

Biogen (BUE:BIIB) Headlines

From GuruFocus

Q2 2021 Biogen Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Biogen Inc Investor Day Transcript

By GuruFocus Research 01-22-2024

Biogen Inc at Stifel CNS Days (Virtual) Transcript

By GuruFocus Research 01-22-2024

Biogen Inc at JPMorgan Healthcare Conference Transcript

By GuruFocus Research 01-22-2024

Biogen Inc at Stifel CNS Days (Virtual) Transcript

By GuruFocus Research 01-22-2024

Q2 2022 Biogen Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024